Unknown

Dataset Information

Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma.


ABSTRACT: For nearly a decade, sorafenib has served as a first-line chemotherapeutic drug for the treatment of hepatocellular carcinoma (HCC), but it displays only limited efficacy against advanced drug-resistant HCC. Regorafenib, the first second-line drug approved for treatment after sorafenib failure, can reverse resistance to sorafenib. We used bioinformatics methods to identify genes whose expression was differentially induced by sorafenib and regorafenib in HCC. We identified KIF14 as an oncogene involved in the acquired resistance to sorafenib in HCC and investigated its potential as a target for reversing this resistance. Sustained exposure of resistant HCC cells to sorafenib activated the AKT pathway, which in turn upregulated KIF14 expression by increasing expression of the transcri

SUBMITTER: Zhu Q 

PROVIDER: S-EPMC7746348 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature